Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

SPINEWAY : Capital increase of €1.6M reserved for Tinavi Medical Technologies

Posted on: 28 Dec 17

Press release                                                                                                                                                    Ecully, 28 December 2017

Capital increase of €1.6M
reserved for Tinavi Medical Technologies

SPINEWAY, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), announces the exercise by Tinavi Medical Technologies (a Chinese company) of share purchase warrants representing €1.6M.

In accordance with the agreement entered into in September 2016, on 27 December 2017, Spineway's Board of Directors approved and recorded the completion of a capital increase reserved for Tinavi Medical Technologies through the issuance of 390 784 new shares without preferential subscription rights representing €1.6M.

This capital increase was fully subscribed for by TINAVI Medical Technologies, which now holds 17.36% of Spineway's capital and 10.59% of its voting rights. The 390 784 new shares will be admitted for trading on Euronext Growth on 2 January 2018.

Furthermore, the nomination of TINAVI Medical Technologies (or one of its representatives) as a Board member will be submitted at Spineway's next shareholders' meeting.

This press release is available in both English and French. In case of discrepancy, the French version shall prevail.

Find out all about Spineway at


Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its turnover comes from exports .
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), received the OSEO Excellence award as well as the Deloitte Fast 50 award in 2011. Rhône Alpes INPI Patent Innovation Award (2013) - Talent INPI award (2015) .
ISIN code: FR0011398874 - Euronext Growth


                        Investor Relations
David Siegrist - Finance Director
+33 (0)4 72 77 01 52
  Financial Communication
Jérôme Gacoin / Solène Kennis
+33 (0)1 75 77 54 68
Tinavi capital increase December 2017

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: SPINEWAY via GlobeNewswire

Last updated on: 30/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.